<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03410446</url>
  </required_header>
  <id_info>
    <org_study_id>INKeD-PC</org_study_id>
    <nct_id>NCT03410446</nct_id>
  </id_info>
  <brief_title>Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care</brief_title>
  <official_title>A Phase II, Open-label Clinical Trial of Intranasal Ketamine for Depression in Patients With Cancer Receiving Palliative Care (INKeD-PC Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 study of the drug ketamine for the treatment of depression in cancer
      patients receiving palliative care. The purpose of this study is to see how useful the drug
      is at decreasing the severity of depression these patients. Ketamine will be given through
      the nose.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Greater than 25% of participants achieving a clinical response</measure>
    <time_frame>Day 8</time_frame>
    <description>Montgomery-Åsberg Depression Rating Scale (MADRS) score decreasing by &gt;50%</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Depression</condition>
  <condition>Cancer</condition>
  <condition>Palliative Care</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of ketamine will be given intranasal:
Dose 1 will be 50 mg on Day 1
Dose 2 will be between 50-100 mg on Day 4
Dose 3 will be between 50-150 mg on Day 7</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine Hydrochloride</intervention_name>
    <description>Ketamine is a N-methyl-D-aspartate (NMDA) antagonist.</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written, voluntary informed consent prior to study enrollment. Participants
             must be capable of consenting to treatment as substitute decision makers will not be
             allowed to consent to the study on their behalf

          -  Males and females between the ages of 18 and 75.

          -  Patient is an inpatient of the Princess Margaret Cancer Centre's (PM) palliative care
             unit (PCU).

          -  Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
             criteria for Major Depressive Disorder (MDD), with a current Major Depressive Episode
             (MDE)

          -  Depression severity must be in the moderate to severe range, as determined by a
             Montgomery-Åsberg Depression Rating Scale (MADRS) score greater than or equal to 20

          -  Participants must have a confirmed diagnosis of cancer and an estimated life
             expectancy of less than six months, as determined by the inpatient palliative care
             physician

        Exclusion Criteria:

          -  Presence of delirium or suspected delirium

          -  Severe hypertension or severe cardiac decompensation

          -  Previous stroke history

          -  History of intolerability, hypersensitivity or allergy to ketamine

          -  Patients with bipolar disorder, psychotic disorders, substance use disorders or active
             suicidality based on a Mini-International Neuropsychiatric Interview (MINI) conducted
             by delegated physician will also be excluded

          -  Current symptoms of psychosis or perceptual disturbances of any kind per investigator
             discretion

          -  Pregnancy or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madeline Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Madeline Li, M.D.</last_name>
    <phone>416-946-4501</phone>
    <phone_ext>7505</phone_ext>
    <email>madeline.li@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Madeline Li, M.D.</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>7505</phone_ext>
      <email>madeline.li@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Madeline Li, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2018</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

